| 120 | 5 | 63 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:观察康柏西普与雷珠单抗对湿性年龄相关性黄斑变性(wt-AMD)1型脉络膜新生血管(CNV)的临床疗效。方法:对2016年1月~2019年7月在我院确诊为wt-AMD 1型CNV的40眼,根据接受治疗的药物分成康柏西普与雷珠单抗两组,每组各20眼,并按照3+PRN原则进行治疗。对比分析治疗前、治疗3月、治疗6月的视力、黄斑中央区视网膜平均厚度(CRT)及视网膜下积液(SRF)变化情况。结果:两组患者基线视力和CRT均无统计学差异(均P>0.05)。康柏西普组和雷珠单抗组治疗6月后视力和CRT均较前明显改善(均P<0.05)。但治疗3月和治疗6月后,在视力和CRT的变化方面,两组之间均无统计学差异(均P>0.05)。患者治疗6月后的视力及变化量均与基线视力有关(均P<0.001)。治疗3月与治疗6月后,两组SRF均无明显改善(均P>0.05)。结论:康柏西普和雷珠单抗均能有效改善wt-AMD 1型CNV患者的视力,减少CRT,且视力改善与基线视力密切相关。
Abstract：Objective: To explore the effects of conbercept and ranibizumab on type 1 choroidal neovascularization(CNV)in wet age-related macular degeneration(wt-AMD).Methods:A total of 40 eyes diagnosed as type 1 CNV of wt-AMD in our hospital from January 2016 to July 2019,were divided into the conbercept group and the ranibizumab group,with 20 eyes in each group.All cases were treated according to the 3+PRN principles.Then,the changes of visual acuity,central retinal thickness(CRT)and subretinal fluid(SRF)were observed before treatment,3 months and 6 months after treatment,respectively.Results:There were no significant differences between two groups in baseline of visual acuity and CRT(both P >0.05).After 6 months of treatment,the visual acuity and CRT in conbercept and ranibizumab group were all improved significantly compared with the previous,respectively(all P <0.05).However,there were no significant differences between two groups in the changes of visual acuity and CRT on 3 or 6 months after treatment(all P>0.05).The visual acuity and its change on 6 months after treatment were both related to the baseline level(both P<0.001).In the two groups,there was no significant difference in SRF at 3 or 6 months after treatment compared with the previous(all P >0.05).Conclusion:Both conbercept and ranibizumab could increase visual acuity and reduce CRT in patients with type 1 CNV,effectively.And the visual improvement is closely related to the baseline visual acuity.
[1] Abedi F,Wickremasinghe S,Islam A F,et al.AntiVEGF treatment in neovascular age-related macular degeneration:a treat-and-extend protocol over 2years[J].Retina,2014,34(8):1531-1538.
[2] Toth L A,Stevenson M,Chakravarthy U,et al.Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration[J].Retina,2015,35(10):1957-1963.
[3] Mitchell P,Liew G,Gopinath B,et al.Age-related macular degeneration[J].Lancet,2018,392(10153):1147-1159.
[4] Lambert N G,Elshelmani H,Singh M K,et al.Progress in retinal and eye research risk factors and biomarkers of age-related macular degeneration[J].Prog Retin Eye Res,2016,54:64-102.
[5] Kataoka K,Takeuchi J,Nakano Y,et al.Characteristics and classification of type 3neovascularization with B-scan flow overlay and en face flow images of optical coherence tomography angiography[J].Retina,2020,40(1):109-120.
[6] Mentes J,Karaca I,Sermet F.Multimodal imaging characteristics of quiescent type 1neovascularization in an eye with angioid streaks[J].Am J Ophthalmol Case Rep,2018,10:132-136.
[7] Kuehlewein L,Bansal M,Lenis T L,et al.Optical coherence tomography angiography of type 1neovascularization in age-related macular degeneration[J].Am J Ophthalmol,2015,160(4):739-748.
[8] Richard F Spaide.Choroidal neovascularization[J].Retina,2017,37(4):609-610.
[9] Guymer R H,Markey C M,McAllister I L,et al.Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat and extend regimen:fluid study 24 month results[J].Ophthalmology,2019,126(5):723-734.
[10]Freund K B,Zweifel S A,Engelbert M.Do we need a new classification for choroidal neovascularization in age-related macular degeneration[J].Retina,2010,30(9):1333-1349.
[11] Wong C W,Yanagi Y,Lee W K,et al.Age-related macular degeneration and polypoidal choroidal vasculopathy in asians[J].Prog Retin Eye Res,2016,53:107-139.
[12]Kenneth T E,Kertes P J.Ranibizumab in neovascular age-related macular degeneration[J].Clin Interv Aging,2006,1(4):451-466.
[13]Tano Y,Ohji M.EXTEND-I:Safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration[J].Acta Ophthalmol,2010,88(3):309-316.
[14]Wang Q,Li T,Wu Z G,et al.Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J].PLoS One,2013,8(8):e70544.
[15]Peden M C,Suner I J,Hammer M E,et al.Long-term outcomes in eyes receiving fixed-interval dosing of antivascular endothelial growth factor agents for wet agerelated macular degeneration[J].Ophthalmology,2015,122(4):803-808.
[16]Li X,Xu G,Wang Y,et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration:Results from a 12-month randomized phase 2Study:AURORA study[J].Ophthalmology,2014,121(9):1740-1747.
[17]Jia Y,Bailey S T,Hwang T S,et al.Quantitative optical coherence tomography angiography of vascular abnormalities in the living human eye[J].Proc Natl Acad Sci USA,2015,112(18):E2395-2402.
[18]Grossniklaus H E,Gass J D.Clinicopathologic correlations of surgically excised type 1and type 2submacular choroidal neovascular membranes[J].Am J Ophthalmol,1998,126(1):59-69.
基本信息:
中图分类号:R774.5
引用信息:
[1]吴昊,刘帅,覃勉,等.康柏西普与雷珠单抗治疗湿性年龄相关性黄斑变性1型脉络膜新生血管的临床研究[J].巴楚医学,2020,3(01):39-43.
基金信息:
国家自然科学基金项目(No:81770920)
2020-03-30
2020-03-30